Adam Stern Net Worth

The estimated Net Worth of Adam K Stern is at least $54.8 Tausend dollars as of 1 March 2021. Mr. Stern owns over 619 units of DarioHealth Corp stock worth over $54,779 and over the last 14 years he sold DRIO stock worth over $0. In addition, he makes $0 as Director at DarioHealth Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Stern DRIO stock SEC Form 4 insiders trading

Adam has made over 28 trades of the DarioHealth Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 619 units of DRIO stock worth $489 on 1 March 2021.

The largest trade he's ever made was exercising 278,407 units of DarioHealth Corp stock on 3 April 2020 worth over $139,204. On average, Adam trades about 15,783 units every 25 days since 2010. As of 1 March 2021 he still owns at least 69,341 units of DarioHealth Corp stock.

You can see the complete history of Mr. Stern stock trades at the bottom of the page.

Adam Stern biography

Adam K. Stern serves as Director of the Company. Mr. Stern has been the head Private Equity Banking at Aegis Capital Corp. and CEO of SternAegis Ventures since 2012 and was a member of our board of directors between October 2011 and May 2014. Prior to Aegis, from 1997 to November 2012, he was with Spencer Trask Ventures, Inc., most recently as a Senior Managing Director, where he managed the structured finance group focusing primarily on the technology and life science sectors. Mr. Stern held increasingly responsible positions from 1989 to 1997 with Josephthal & Co., Inc., members of the New York Stock Exchange, where he served as Senior Vice President and Managing Director of Private Equity Marketing. He has been a FINRA licensed securities broker since 1987 and a General Securities Principal since 1991. Mr. Stern is a director of Aerami Therapeutics Holdings (formerly Dance Biopharm, Inc.), Matinas BioPharma Holdings, Inc. Adgero Biopharmaceuticals Holdings and Hydrofarm Holdings Group, Inc. Mr. Stern is a former director of InVivo Therapeutics Holdings Corp. (OTCQB: NVIV), Organovo Holdings, Inc. (NYSE MKT: ONVO) and PROLOR Biotech Ltd., which was sold to Opko Health, Inc. (NYSE: OPK) for approximately $600 million in 2013. Mr. Stern holds a Bachelor of Arts degree with honors from The University of South Florida in Tampa.

How old is Adam Stern?

Adam Stern is 56, he's been the Director of DarioHealth Corp since 2020. There are 6 older and 10 younger executives at DarioHealth Corp. The oldest executive at DarioHealth Corp is Richard Stone, 77, who is the Independent Director.

What's Adam Stern's mailing address?

Adam's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at DarioHealth Corp

Over the last 9 years, insiders at DarioHealth Corp have traded over $4,057,564 worth of DarioHealth Corp stock and bought 2,163,162 units worth $794,618 . The most active insiders traders include Erez Raphael, Adam K Stern und Yoav Shaked. On average, DarioHealth Corp executives and independent directors trade stock every 33 days with the average trade being worth of $20,360. The most recent stock trade was executed by Steven Charles Nelson on 5 September 2024, trading 15,000 units of DRIO stock currently worth $12,300.

What does DarioHealth Corp do?

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.

Complete history of Mr. Stern stock trades at DarioHealth Corp, InVivo Therapeutics Corp, Organovo Inc und Matinas Biopharma Inc

DarioHealth Corp executives and stock owners

DarioHealth Corp executives and other stock owners filed with the SEC include:

• Erez Raphael,
  Chief Executive Officer, Director
• Erez Raphael,
  CEO & Director
• Richard A. Anderson,
  Pres & GM of North America
• Dror Bacher,
  Chief Operating Officer
• Zvi Ben-David,
  Chief Financial Officer, Treasurer, Secretary
• Olivier Jarry,
  Senior Vice President - Strategy and Business Development
• Dror Bacher,
  Chief Operating Officer
• Zvi Ben David,
  CFO, Treasurer & Sec.
• Richard Stone,
  Independent Director
• Dennis McGrath,
  Independent Director
• Hila Karah,
  Independent Director
• Dennis Matheis,
  Director
• Omar Manejwala,
  Chief Medical Officer
• Barbara Stark,
  Senior Vice President, Head of Managed Markets
• Adam Stern,
  Director
• Yadin Shemmer,
  Independent Director
• Richard Anderson,
  President, General Manager - North America
• Allen Kamer,
  Independent Director
• Yoav Shaked,
  Independent Chairman of the Board
• Limor Drezner,
  VP HR & Chief of Staff
• Josh Fischer,
  Sr. VP of Operations & Compliance
• Yinon Amir,
  Head of Software Innovation
• Jean Christophe Muyl,
  Head of Commercialization North America
• Suzanne Bedell,
  VP of Marketing
• Claudia Levi,
  Content & Communications Mang.
• Dov Oppenheim,
  Co-Founder & Production Chief
• Olivier R. Jarry,
  Sr. VP of Strategy & Bus. Devel.
• Hod Rami Yehudiha,
  Director
• Glen Moller,
  Director
• Yalon Farhi,
  Director
• Malcolm Hoenlein,
  Director
• Ori Zanco,
  Director
• Yossi Bahagon,
  Director
• Shmuel Farhi,
  10% owner
• Yossef Balucka,
  CEO and President
• Oded Cohen,
  GM MSK
• Jon H. Kaplan,
  Director
• Tomer Ben Kiki,
  Chief Operating Officer
• Steven Charles Nelson,
  Chief Commercial Officer